Premera Blue Cross is soliciting stakeholder feedback by March 5, 2026 on a broad set of medical policies, including several MDC 01 Neurology & Nervous System items (Deep Brain Stimulation 7.01.63; Ablative Treatments for Occipital Neuralgia, Chronic Headaches, and Atypical Facial Pain 7.01.563; Pulsed Radiofrequency for Chronic Pain 7.01.564; Artificial Intervertebral Disc: Lumbar Spine 7.01.589). The notice lists policy numbers and titles but does not include draft language, proposed coverage criteria, coding changes, or rationale for revisions. This publication functions solely as a request for feedback on the enumerated policies within a larger multidisciplinary review list. Providers should note the March 5, 2026 deadline if they wish to submit input on these neurology/spine and pain management policies.
March 5, 2026 Revision: Solicitation of Feedback on Listed Policies
This document lists a set of policies for which Premera Blue Cross is soliciting feedback by March 5, 2026. The notice explicitly repeats the deadline twice and includes multiple policy numbers and titles across clinical areas. Among the listed items are neurologic and spine-related policies such as 7.01.63 Deep Brain Stimulation, 7.01.563 Ablative Treatments for Occipital Neuralgia, Chronic Headaches, and Atypical Facial Pain, and 7.01.589 Artificial Intervertebral Disc: Lumbar Spine.
No clinical coverage criteria, coding changes, or specific language revisions are provided in the text. The only clear change communicated by this document is the solicitation window for stakeholder feedback (deadline: March 5, 2026) for the enumerated policies; the document does not include redlines, amended criteria, or explicit policy content revisions themselves.
Inclusion of MDC 01 Neurology & Nervous System Topics in Review List
The document enumerates neurologic and neurosurgical items among a broader list of policies: 7.01.63 Deep Brain Stimulation, 7.01.563 Ablative Treatments for Occipital Neuralgia, Chronic Headaches, and Atypical Facial Pain, 7.01.564 Pulsed Radiofrequency for the Treatment of Chronic Pain, and 7.01.589 Artificial Intervertebral Disc: Lumbar Spine. These appear within the larger set of policies presented for review, indicating these specific MDC 01 (Neurology & Nervous System) topics are included in the review cycle.
No further detail is provided about proposed modifications to clinical indications, coverage criteria, or procedural coding for these neurologic/spine policies. The listing functions as an index of items under consideration rather than an exposition of substantive content changes.
Scope: Broad Multi-Disciplinary Review List Including Pain and Spine Interventions
The authoritative text is a consolidated list of many policy numbers and titles across several service lines (wound care, audiology, dermatology, cardiology, nutrition testing, pain management, orthopedics, bariatrics, reconstructive surgery, hematopoietic cell transplantation, and stem cell therapies). Policies relevant to pain management and ablative treatments are explicitly named: 7.01.563 Ablative Treatments for Occipital Neuralgia, Chronic Headaches, and Atypical Facial Pain and 7.01.564 Pulsed Radiofrequency for the Treatment of Chronic Pain.
The document does not supply any accompanying rationale, evidence summaries, or proposed policy language for these topics. It therefore should be read as a call for feedback on the listed titles rather than a presentation of finalized policy revisions.
Administrative Notice and Limitations: Deadline and Lack of Draft Language
Administrative details in the text are limited to the deadline and the list of policies under review. The notice repeats the instruction "Please submit your feedback by March 5, 2026" at the beginning and again mid-document, emphasizing the timeframe for stakeholder input. Policy numbers are provided for precise identification (for example, 7.01.589 for artificial intervertebral disc of the lumbar spine), but no contact mechanism, submission instructions, or proposed effective dates for any eventual changes are included.
Because the document lacks substantive policy content or draft language, there are no listed changes to coverage criteria, CPT codes, medical necessity definitions, or criteria for utilization management. The publication functions purely as an advance notice and a request for feedback on the enumerated policies.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.